Formatech, Inc. to Donate Services to Formulate and Fill Femta Pharmaceuticals’ FM101 Monoclonal Antibody under Its "Fillanthropy(TM) Program"  
7/30/2010 11:26:28 AM

ANDOVER, Mass.--(BUSINESS WIRE)--Today, Formatech, Inc. announced that it has selected Femta’s FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta’s upcoming clinical trials.